IN2012DN05101A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN05101A IN2012DN05101A IN5101DEN2012A IN2012DN05101A IN 2012DN05101 A IN2012DN05101 A IN 2012DN05101A IN 5101DEN2012 A IN5101DEN2012 A IN 5101DEN2012A IN 2012DN05101 A IN2012DN05101 A IN 2012DN05101A
- Authority
- IN
- India
- Prior art keywords
- igf
- seq
- antibodies
- cdr sequences
- chain cdr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Abstract
The present invention provides compositions and methods of use of anti-IGF-1R antibodies or fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R; effectively neutralize activation of IGF-1R by IGF- 1 in intact cells; block binding of R1 antibody to IGF-1 R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising heavy chain CDR sequences DYYMY (SEQ ID NO:l), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (seq id no:3) and light chain CDR sequences KASQEVGTAVA (seq id no:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 15 1-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer. FIG. 138 ME-180
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2010021345 | 2010-01-19 | ||
PCT/US2010/027155 WO2011090492A1 (en) | 2010-01-19 | 2010-03-12 | Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN05101A true IN2012DN05101A (en) | 2015-10-23 |
Family
ID=44307101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN5101DEN2012 IN2012DN05101A (en) | 2010-01-19 | 2010-03-12 |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP3075390A1 (en) |
JP (1) | JP5786204B2 (en) |
CN (1) | CN102725000B (en) |
AU (1) | AU2010343304B2 (en) |
CA (1) | CA2787074A1 (en) |
IN (1) | IN2012DN05101A (en) |
WO (1) | WO2011090492A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9862770B2 (en) | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
EP2748613B1 (en) | 2011-10-07 | 2021-05-05 | Baxalta GmbH | Oxmif as a diagnostic marker |
CA2855566A1 (en) | 2011-12-02 | 2013-06-06 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors |
AU2013202693B2 (en) * | 2012-04-16 | 2015-01-22 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics |
AU2013312211B2 (en) | 2012-09-07 | 2018-03-29 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
CA2935378C (en) * | 2013-12-24 | 2023-04-18 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
BR112017005988A2 (en) * | 2014-09-26 | 2017-12-19 | Macrogenics Inc | cd19 x cd3 bispecific monovalent fc diabody capable of specific binding to cd19 and cd3, covalently associated polypeptide complex, pharmaceutical composition, and use of the pharmaceutical composition |
GB201501930D0 (en) * | 2015-02-05 | 2015-03-25 | Univ London Queen Mary | Biomarkers for pancreatic cancer |
JP7184751B2 (en) | 2016-04-15 | 2022-12-06 | イミュネクスト インコーポレイテッド | ANTI-HUMAN VISTA ANTIBODY AND USES THEREOF |
AU2017311927B2 (en) * | 2016-08-16 | 2021-06-03 | National Institute Of Advanced Industrial Science And Technology | Malignant tumor target peptide |
EA201992595A1 (en) | 2017-05-05 | 2020-04-21 | Фьюжн Фармасьютикалс Инк. | STRENGTHENING OF PHARMACOKINETICS OF BIFUNCTIONAL CHELATES AND THEIR APPLICATION |
JP7191938B2 (en) * | 2017-05-05 | 2022-12-19 | センター・フォー・プローブ・デベロップメント・アンド・コマーシャライゼイション | IGF-1R monoclonal antibody and use thereof |
CA3068841A1 (en) | 2017-07-03 | 2019-01-10 | Torque Therapeutics, Inc. | Fusion molecules targeting immune regulatory cells and uses thereof |
CN113512116B (en) * | 2020-04-10 | 2022-09-20 | 苏州普乐康医药科技有限公司 | anti-IGF-1R antibody and application thereof |
CN113061191B (en) * | 2021-03-17 | 2023-03-24 | 托比康尔生物科技(武汉)有限公司 | IgG-like three-functional antibody and application thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5252296A (en) | 1990-05-15 | 1993-10-12 | Chiron Corporation | Method and apparatus for biopolymer synthesis |
US5492807A (en) | 1993-11-19 | 1996-02-20 | Santi; Daniel V. | Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease |
US6310185B1 (en) * | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
US6068829A (en) | 1995-09-11 | 2000-05-30 | The Burnham Institute | Method of identifying molecules that home to a selected organ in vivo |
US5622699A (en) | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
US6737249B1 (en) * | 1997-08-22 | 2004-05-18 | Genentech, Inc. | Agonist antibodies |
US7279160B2 (en) * | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
US7329745B2 (en) * | 2000-06-13 | 2008-02-12 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
WO2004009805A1 (en) * | 2002-07-19 | 2004-01-29 | Japan Science And Technology Agency | Novel process for producing antibody enzyme, novel antibody enzyme and utilization thereof |
BRPI0408317A (en) * | 2003-03-14 | 2006-03-07 | Pharmacia Corp | igf-i receptor antibodies for cancer treatment |
ATE514434T1 (en) * | 2004-02-25 | 2011-07-15 | Dana Farber Cancer Inst Inc | INSULIN-LIKE GROWTH FACTOR RECEPTOR-1 INHIBITOR FOR INHIBITING TUMOR CELL GROWTH |
MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
JP5657862B2 (en) * | 2005-07-28 | 2015-01-21 | ノバルティス アーゲー | Use of antibodies against M-CSF |
CA2607056C (en) * | 2005-10-19 | 2015-11-24 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
AU2007245164A1 (en) * | 2006-03-28 | 2007-11-08 | Biogen Idec Ma Inc. | Anti-IGF-IR antibodies and uses thereof |
GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
WO2009126304A1 (en) * | 2008-04-11 | 2009-10-15 | Biogen Idec Ma Inc. | Therapeutic combinations of anti-igf-1r antibodies and other compounds |
-
2010
- 2010-03-12 WO PCT/US2010/027155 patent/WO2011090492A1/en active Application Filing
- 2010-03-12 EP EP16001044.3A patent/EP3075390A1/en not_active Withdrawn
- 2010-03-12 EP EP10844115.5A patent/EP2525820B1/en active Active
- 2010-03-12 CA CA2787074A patent/CA2787074A1/en not_active Abandoned
- 2010-03-12 AU AU2010343304A patent/AU2010343304B2/en not_active Ceased
- 2010-03-12 IN IN5101DEN2012 patent/IN2012DN05101A/en unknown
- 2010-03-12 JP JP2012549978A patent/JP5786204B2/en active Active
- 2010-03-12 CN CN201080061420.0A patent/CN102725000B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN102725000A (en) | 2012-10-10 |
WO2011090492A1 (en) | 2011-07-28 |
CA2787074A1 (en) | 2011-07-28 |
EP2525820A1 (en) | 2012-11-28 |
EP3075390A1 (en) | 2016-10-05 |
EP2525820B1 (en) | 2016-05-11 |
JP2013516996A (en) | 2013-05-16 |
EP2525820A4 (en) | 2013-08-21 |
CN102725000B (en) | 2015-10-07 |
AU2010343304B2 (en) | 2013-06-20 |
JP5786204B2 (en) | 2015-09-30 |
AU2010343304A1 (en) | 2012-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN05101A (en) | ||
JOP20200213A1 (en) | PD-1-Binding Molecules and Methods of Use Thereof | |
MY190771A (en) | Anti-pd-l1 antibodies and uses thereof | |
MX2020004410A (en) | Antibody compositions for tumor treatment. | |
WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
MD3353212T2 (en) | Optimized anti-cd3 bispecific antibodies and uses thereof | |
HRP20161656T4 (en) | Cd33 binding agents | |
MX2010010387A (en) | Bcr-complex-specific antibodies and methods of using same. | |
MX2009010120A (en) | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof. | |
NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
EA201070596A1 (en) | HUMANIZED ANTIBODIES AGAINST TL1A | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
MD4716B1 (en) | Anti-LAG3 antibodies and antigen-binding fragments | |
PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
NZ607710A (en) | 4-1bb binding molecules | |
NZ626610A (en) | Antibodies that bind csf1r | |
AU2018338418A1 (en) | Anti-HLA-A2 antibodies and methods of using the same | |
NZ715896A (en) | Humanized or chimeric cd3 antibodies | |
MY166776A (en) | Humanised anti-ctla4 antibodies | |
MX2015013194A (en) | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor. | |
NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
MX2009012493A (en) | Novel rabbit antibody humanization methods and humanized rabbit antibodies. | |
MX341958B (en) | Antibodies against human il33r and uses thereof. | |
EP2579895A4 (en) | Anti-vegf antibodies and uses thereof |